Company intelligence / Profile preview

Inspira Technologies

Ra’anana, Central District, Israelinspira-technologies.com ↗

Ownership: Public · IINN
Employees: ~30
Development stage: Preclinical

Overview

Inspira Technologies has received FDA 510(k) clearance for its INSPIRA ART100 system—a cardiopulmonary bypass device now being deployed in U.S. hospitals. The company’s AI-powered HYLA blood sensor demonstrated 96% accuracy compared to standard analyzers in a clinical study at Sheba Medical Center. The next-generation INSPIRA ART500 remains under development with plans for further clinical studies and regulatory submissions in 2025.

Therapeutic areas: PulmonologyCardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Glo-Med Networks Inc. (U.S. distribution)Innovimed SpA z o.o (planned clinical trials in Europe)

Financials

Market cap: $25.3M
Total revenue: $144.5K
Enterprise value: $22.6M

Beyond the preview

Go deeper on Inspira Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inspira Technologies.

Explore the full profile